News
News

The latest updates from AFAR.

Board Member in the News: David Sinclair on Senolytics in The Boston Herald

Sep 12
2017

Board Member in the News: David Sinclair on Senolytics in The Boston Herald View MoreBACK

A September 9, 2017 story in The Boston Herald featured insights by 2000 AFAR Research Grant recipient and Board member David Sinclair, PhD on the potential of senolytic drugs to transform how we age.

Despite the article’s claims of “eternal youth” promised by “anti-aging therapies,” Dr. Sinclair speaks on the evidence-based science recently published by 2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient and President-elect James L. Kirkland, MD, PhD in the Journal of the American Geriatrics Society article The Clinical Potential of Senolytic Drugs.

Dr. Sinclair notes: “I see a future where people will go in and have a dose of this, and reset their clock,” said Harvard University geneticist David Sinclair. “This is one of the biggest developments in the last decade in aging research and in medicine. If it works, it will be transformational for human health.”

Read The Boston Herald story here.

David A. Sinclair, PhD is as a Professor of Genetics and co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School.


For more information on senescent cells, we encourage you to explore our expert-edited Infoaging Guide to Cellular Senescence here.





View MoreBACK TO TOP